Notice of Meeting, 33315 [2010-13982]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 112 / Friday, June 11, 2010 / Notices
Therefore, in accordance with 5 CFR
1320.3(c), the reporting requirements in
this notice are not defined as
information collection requirements.
(Catalog of Federal Domestic Assistance
Program No. 93.773, Medicare—Hospital
Insurance; Program No. 93.774, Medicare—
Supplementary Medical Insurance, and
Program No. 93.778, Medical Assistance
Program)
Dated: June 3, 2010.
Marilyn Tavenner,
Acting Administrator and Chief Operating
Officer, Centers for Medicare & Medicaid
Services.
[FR Doc. 2010–14098 Filed 6–10–10; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Date: July 2, 2010. (Open on July 2
from 8 a.m. to 8:15 a.m. and closed for
the remainder of the meeting.)
Place: Hyatt Regency Bethesda Hotel,
7400 Wisconsin Avenue, 1 Bethesda
Metro Center, Conference Room TBD,
Bethesda, MD 20814.
Contact Person: Anyone wishing to
obtain a roster of members, agenda or
minutes of the non-confidential portions
of this meeting should contact Mrs.
Bonnie Campbell, Committee
Management Officer, Office of
Extramural Research, Education and
Priority Populations, AHRQ, 540
Gaither Road, Room 2038, Rockville,
Maryland 20850, Telephone (301) 427–
1554.
Agenda items for this meeting are
subject to change as priorities dictate.
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: May 27, 2010.
Carolyn M. Clancy,
Director.
Dental Products Panel of the Medical
Devices Advisory Committee; Notice of
Meeting
Dated: June 4, 2010.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2010–14074 Filed 6–10–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0268]
[FR Doc. 2010–13982 Filed 6–10–10; 8:45 am]
AGENCY:
BILLING CODE 4160–90–M
HHS.
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
Notice of Meeting
ACTION:
In accordance with section 10(d) of
the Federal Advisory Committee Act (5
U.S.C., Appendix 2), announcement is
made of a Health Care Policy and
Research Special Emphasis Panel (SEP)
meeting.
A Special Emphasis Panel is a group
of experts in fields related to health care
research who are invited by the Agency
for Healthcare Research and Quality
(AF[RQ), and agree to be available, to
conduct on an as needed basis,
scientific reviews of applications for
AHRQ support. Individual members of
the Panel do not attend regularlyscheduled meetings and do not serve for
fixed terms or a long period of time.
Rather, they are asked to participate in
particular review meetings which
require their type of expertise.
Substantial segments of the upcoming
SEP meeting listed below will be closed
to the public in accordance with the
Federal Advisory Committee Act,
section 10(d) of 5 U.S.C., Appendix 2
and 5 U.S.C. 552b(c)(6). Grant
applications for the OS ARRA:
Clinically-Enhanced State Data for
Analysis for CE Impact (R01)
applications are to be reviewed and
discussed at this meeting. These
discussions are likely to reveal personal
information concerning individuals
associated with the applications. This
information is exempt from mandatory
disclosure under the above-cited
statutes.
SEP Meeting on: OS ARRA:
Clinically-Enhanced State Data for
Analysis for CE Impact (R01).
VerDate Mar<15>2010
15:04 Jun 10, 2010
Jkt 220001
33315
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Research 2
Practice and Construction Research
Application, Request for Application
(RFA) OH09–001, Initial Review
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the aforementioned meeting:
Time and Date: 3 a.m.–5 p.m., July 7, 2010
(Closed).
Place: National Institute for Occupational
Safety and Health (NIOSH), 2400 Century
Parkway, NE., Fourth Floor, Atlanta, Georgia
30345, Telephone: (404) 498–2530.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5,
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Section 10(d) of Public Law
92–463.
Matters To Be Discussed: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘Research 2 Practice and
Construction Research Application, RFA
OH09–001’’.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information: Chris
Langub, PhD, Scientific Review Officer,
NIOSH, CDC, 2400 Century Center, Atlanta,
GA 30333, Telephone: (404) 498–2543.
The Director, Management Analysis and
Services Office has been delegated the
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
Food and Drug Administration,
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Dental Products
Panel of the Medical Devices Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on December 14 and 15, 2010, from
8 a.m. to 6 p.m.
Location: Holiday Inn-Gaithersburg,
Main Ballroom, 2 Montgomery Village
Ave., Gaithersburg, MD 20879.
Contact Person: Olga I. Claudio, Food
and Drug Administration, Center for
Devices and Radiological Health, WO
66, rm. 1553, Silver Spring, MD 20993–
0002, 301–796–7608 or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area), code 301–451–
2518. Please call the Information Line
for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Comments: FDA is opening a docket
for public comment on this document.
E:\FR\FM\11JNN1.SGM
11JNN1
]]>Agencies
[Federal Register Volume 75, Number 112 (Friday, June 11, 2010)]
[Notices]
[Page 33315]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-13982]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Notice of Meeting
In accordance with section 10(d) of the Federal Advisory Committee
Act (5 U.S.C., Appendix 2), announcement is made of a Health Care
Policy and Research Special Emphasis Panel (SEP) meeting.
A Special Emphasis Panel is a group of experts in fields related to
health care research who are invited by the Agency for Healthcare
Research and Quality (AF[RQ), and agree to be available, to conduct on
an as needed basis, scientific reviews of applications for AHRQ
support. Individual members of the Panel do not attend regularly-
scheduled meetings and do not serve for fixed terms or a long period of
time. Rather, they are asked to participate in particular review
meetings which require their type of expertise.
Substantial segments of the upcoming SEP meeting listed below will
be closed to the public in accordance with the Federal Advisory
Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C.
552b(c)(6). Grant applications for the OS ARRA: Clinically-Enhanced
State Data for Analysis for CE Impact (R01) applications are to be
reviewed and discussed at this meeting. These discussions are likely to
reveal personal information concerning individuals associated with the
applications. This information is exempt from mandatory disclosure
under the above-cited statutes.
SEP Meeting on: OS ARRA: Clinically-Enhanced State Data for
Analysis for CE Impact (R01).
Date: July 2, 2010. (Open on July 2 from 8 a.m. to 8:15 a.m. and
closed for the remainder of the meeting.)
Place: Hyatt Regency Bethesda Hotel, 7400 Wisconsin Avenue, 1
Bethesda Metro Center, Conference Room TBD, Bethesda, MD 20814.
Contact Person: Anyone wishing to obtain a roster of members,
agenda or minutes of the non-confidential portions of this meeting
should contact Mrs. Bonnie Campbell, Committee Management Officer,
Office of Extramural Research, Education and Priority Populations,
AHRQ, 540 Gaither Road, Room 2038, Rockville, Maryland 20850, Telephone
(301) 427-1554.
Agenda items for this meeting are subject to change as priorities
dictate.
Dated: May 27, 2010.
Carolyn M. Clancy,
Director.
[FR Doc. 2010-13982 Filed 6-10-10; 8:45 am]
BILLING CODE 4160-90-M
